Ultime notizie per Cue Biopharma (NASDAQ:CUE) Azioni

Cue Biopharma

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Cue Biopharma Inc

Cuentas Inc

COPPEREX RES CORP by COPPEREX RES CORP

CUE ENERGY RESOURCES LTD by Cue Energy Resources Ltd.

Citigroup analyst Geoff Meacham downgrades AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) from Buy to Neutral and lowers the price target from $210 to $205.

News

Downgrades

Price Target

Analyst Ratings

ABBV

Citigroup Downgrades AbbVie to Neutral, Lowers Price Target to $205

Earnings Outlook
The Company has raised its full-year 2025 guidance for new transaction funding outside of the Lennar Master Program to $1.5 billion, up from the previously announced $1 billion, driven by heightened demand.
Accordingly, the Company has also increased year-end quarterly earnings per share run-rate to a range of $0.69 to $0.71.

Guidance

Raised Its FY25 Guidance For New Transaction Funding Outside Of The Lennar Master Program To $1.5B, Up From The Previously Announced $1B, Driven By Heightened Demand;  Increased Year-End Quarterly Earnings Per Share Run-Rate To A Range Of $0.69 To $0.71.

Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable safety profile
SEATTLE, May 14, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4427161-1&amp;h=1470666501&amp;u=https%3A%2F%2Fatossatherapeutics.com%2F&amp;a=Atossa+Therapeutics%2C+Inc.">Atossa Therapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today reported full results from the Phase 2 Endocrine Optimization Pilot (EOP) sub‑study within the I‑SPY 2 TRIAL evaluating low‑dose oral (Z)‑endoxifen (10 mg daily) as a neoadjuvant treatment in 20 women with stage II/III estrogen‑receptor–positive (ER+), HER2‑negative breast cancer.

ATOS

Atossa Therapeutics Reports Full Results From Phase 2 EOP Sub‑Study Within I‑SPY 2 Trial Evaluating Low‑Dose Oral (Z)‑Endoxifen As Neoadjuvant Treatment In 20 Women With Stage II/III ER+, HER2‑Negative Breast Cancer

Millrose Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRP#NYSE">MRP</a>) reported quarterly earnings of $0.39 per share.

Earnings

Millrose Properties Q1 EPS $0.39

Antalpha Platform Holding Company ("Antalpha" or the "Company") today announced the pricing of its initial public offering of 3,850,000 ordinary shares at a price to the public of $12.80 per ordinary share. The ordinary shares have been approved for listing and are expected to begin trading on the Nasdaq Global Market on May 14, 2025, under the ticker symbol "ANTA." The offering is expected to close on May 15, 2025, subject to customary closing conditions.
Antalpha has granted the underwriters a 30-day option to purchase an additional 577,500 ordinary shares to cover over-allotments in connection with the offering.

IPOs

ANTA

Antalpha Announces Pricing Of Initial Public Offering Of 3.85M Shares At A Price Of $12.80 Per Share

Citigroup analyst Arthur Truslove downgrades UL Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>) from Buy to Neutral and raises the price target from $60.5 to $71.

Citigroup Downgrades UL Solutions to Neutral, Raises Price Target to $71

IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.38) by 10.53 percent. This is a 13.33 percent decrease over losses of $(0.30) per share from the same period last year.

Earnings Beats

IOBT

IO Biotech Q1 EPS $(0.34) Beats $(0.38) Estimate

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the communication services sector.
<h3 class="wp-block-heading">Shutterstock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSTK#NYSE">SSTK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.83%</li>
<li>JMP Securities analyst Andrew Boone reiterated a Market Perform rating on May 5, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Needham analyst Bernie McTernan maintained a Buy rating and cut the price target from $45 to $30 on March 7, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On May 2, the company posted downbeat quarterly results</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">SSTK news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="896" height="811" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156.png" alt="" class="wp-image-914631" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156.png 896w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156-768x695.png 768w" sizes="(max-width: 896px) 100vw, 896px" /></a></figure>
<h3 class="wp-block-heading">Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.35%</li>
<li>Tigress Financial analyst Ivan Feinseth maintained a Buy rating and raised the price target from $55 to $56 on April 28, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Scotiabank analyst Maher Yaghi maintained a Sector Perform rating and increased the price target from $48.5 to $49 on April 23, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On May 13, Verizon announced a $5 billion commitment to continue investing in America and supporting small businesses.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">latest VZ news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="907" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157.png" alt="" class="wp-image-914632" style="width:698px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157-768x709.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Nexstar Media Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXST#NASDAQ">NXST</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.27%</li>
<li>Benchmark analyst Daniel Kurnos maintained a Buy rating and raised the price target from $215 to $220 on May 9, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Wells Fargo analyst Steven Cahall maintained an Overweight rating and cut the price target from $216 to $200 on May 1, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On May 8, Nexstar Media Group reported better-than-expected first-quarter EPS results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest NXST <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="895" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158.png" alt="" class="wp-image-914635" style="width:671px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158.png 895w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158-768x709.png 768w" sizes="(max-width: 895px) 100vw, 895px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Markets

Trading Ideas

NXST

SSTK

Wall Street's Most Accurate Analysts Spotlight On 3 Tech And Telecom Stocks Delivering High-Dividend Yields

Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) affirms FY2025 sales outlook from $30.00 million to $30.00 million vs $40.20 million estimate.

ALUR

Allurion Technologies Affirms FY2025 Sales Guidance of $30.00M vs $40.20M Est

WIIM

IXHL

Incannex Healthcare shares are trading higher after the company completed patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study of IHL-42X for obstructive sleep apnea.

Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) reported quarterly losses of $(0.66) per share. This is a 1.49 percent increase over losses of $(0.67) per share from the same period last year. The company reported $162.46 thousand in sales this quarter. This is a 57.31 percent decrease over sales of $380.57 thousand the same period last year.

APRE

Aprea Therapeutics Q1 EPS $(0.66) Up From $(0.67) YoY, Sales $162.46K Down From $380.57K YoY

Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.35) by 31.43 percent. This is a 85.37 percent increase over losses of $(1.64) per share from the same period last year.

BNTC

Benitec Biopharma Q3 EPS $(0.24) Beats $(0.35) Estimate

Kalaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLRS#NASDAQ">KLRS</a>) reported quarterly losses of $(2.52) per share which missed the analyst consensus estimate of $(1.17) by 115.38 percent. This is a 3.08 percent increase over losses of $(2.60) per share from the same period last year.

Earnings Misses

KLRS

Kalaris Therapeutics Q1 EPS $(2.52) Misses $(1.17) Estimate

<a href="https://www.globenewswire.com/Tracker?data=VFi76zOPFziMSR2L83lWTcD9X8IU9_hdqO5B40n9RLxP2qqmSR1JF-raa6_Ik_4j4qJiYG-antKeH0DlGMEp7fyTIIWVfSorVwAMNQP3aCc=">Enphase Energy, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced that homeowners in all of New York's major investor-owned electric utility service territories who install Enphase IQ&#xAE; Batteries can now qualify to enroll in the NYSERDA New York Battery Incentive Program. Qualifying homeowners can receive an upfront payment of up to $6,250 through the program.
Homeowners in the Central Hudson, ConEd, NYSEG, National Grid, Orange and Rockland, and Rochester G&amp;E service areas could receive the upfront incentive. Homeowners in the ConEd territory of New York City and Westchester County are eligible for an upfront incentive of $250/kWh, capped at $6,250 per site. For example, customers who install five IQ&#xAE; Battery 5Ps could earn $6,250 upfront. Additionally, homeowners in all other utility territories are eligible for an upfront incentive of $200/kWh, capped at $5,000 per site. Homeowners who install five IQ Battery 5Ps can earn up to $5,000 upfront.

ENPH

Enphase Energy  Announces Homeowners In All Of New York's Major Investor-Owned Electric Utility Service Territories Who Install Enphase IQ Batteries Can Now Qualify To Enroll In The NYSERDA New York Battery Incentive Program

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.
Shares of Alcon Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) fell sharply in today's pre-market trading as the company posted downbeat results for the first <a href="https://www.benzinga.com/quote/ALC">quarter on Tuesday</a>.
Alcon reported quarterly earnings of 73 cents per share which missed the analyst consensus estimate of 75 cents per share. The company reported quarterly sales of $2.45 billion which missed the analyst consensus estimate of $2.51 billion.
The company lowered its FY2025 earnings guidance, but raised its sales guidance.
Alcon shares dipped 5.5% to $87.79 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) shares dipped 16.7% to $6.11 in pre-market trading after Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) announced plans to sell some of its Aurora Innovation stake in a senior notes offering.</li>
<li>GRAIL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) shares fell 14.1% to $36.86 in pre-market trading after reporting weak quarterly sales.</li>
<li>American Eagle Outfitters, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) dipped 13.8% to $10.96 in pre-market trading after the company guided first-quarter revenue down and withdrew FY25 guidance.</li>
<li>Allot Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) declined 8.1% to $7.79 in pre-market trading after gaining 8% on Tuesday.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) dipped 7.5% to $2.33 in pre-market trading after jumping over 12% on Tuesday.</li>
<li>WEBTOON Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) fell 7% to $9.17 in pre-market trading following first-quarter results.</li>
<li>Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) fell 3.2% to $37.77 in pre-market trading.</li>
<li>Pagaya Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) dipped 3.1% to $14.50 in pre-market trading.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Movers

ALLT

GRAL

UBER

WBTN

Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Citigroup analyst Andrew Baum downgrades Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) from Buy to Neutral and lowers the price target from $115 to $84.

Citigroup Downgrades Merck & Co to Neutral, Lowers Price Target to $84

Management

GRRR

Gorilla Technology Group Appoints Bruce Bower As CFO

Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of $(2.03) by 30.54 percent. This is a 66.43 percent increase over losses of $(4.20) per share from the same period last year.

KALA

Kala Bio Q1 EPS $(1.41) Beats $(2.03) Estimate

Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.18) by 77.78 percent. This is a 28.89 percent increase over losses of $(0.45) per share from the same period last year.

Comments

Cue Biopharma

Notizie

Ultime notizie per Cue Biopharma (NASDAQ:CUE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO